Navigation Links
NuVasive Announces Upcoming Departure of Chief Financial Officer
Date:9/2/2009

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President & Chief Financial Officer, has informed NuVasive of his resignation from his position so that he is able to attend to personal and family obligations. The Company is currently engaged in a search for a new Chief Financial Officer. Mr. O'Boyle plans to remain with the Company until December 31, 2009, or potentially longer, to assist in the recruitment of his replacement and to effect an orderly transition.

"I have thoroughly enjoyed serving as part of the management team of NuVasive, helping to build the Company into a major player in the spine industry with a unique culture of Absolute Responsiveness," Mr. O'Boyle said. "Unfortunately, personal obligations make a long term position as CFO of NuVasive extremely difficult to maintain. I would like to thank all NuVasive shareowners for making my time at NuVasive a remarkable one."

Alex Lukianov, Chairman and Chief Executive Officer, said, "Kevin has been part of our executive team for the past 6 years, from fundraising as a private company, to our initial public offering, to helping build our corporate infrastructure for long term growth and continued market share gains. We thank him for his contributions to the Company and wish him well as he attends to important family and personal matters."

Mr. Lukianov continued, "Our financial and business condition is vibrant and healthy as we continue to expand our presence in the market. We have begun the comprehensive search process to identify a new CFO and will be conducting a thorough review to identify the best possible leader to help take us to $1 billion in sales and beyond in concert with expanding profitability and an outstanding financial infrastructure."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel(R) Plus, and the Progentix products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    CONTACT:
    Kevin C. O'Boyle
    EVP & Chief Financial Officer
    NuVasive, Inc.
    +1-858-909-1998
    investorrelations@nuvasive.com

    Investors:
    Patrick F. Williams
    Vice President, Finance
    NuVasive, Inc.
    +1-858-638-5511
    investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    +1-646-536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
9. NuVasive Reports First Quarter 2008 Financial Results
10. NuVasive Acquires First Stem Cell Bone Graft Substitute
11. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Patient ... Baltimore Health System, with the 2017 Ruth Ravich Patient Advocacy Award in ... patient advocates. DeVaro was honored with the award at The Beryl Institute’s annual ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... A Week of Addiction and Recovery Education, from April 24 to April 28, ... substance use disorders. , The mission of AWARE is to instill a ...
(Date:4/21/2017)... UK (PRWEB) , ... April 21, 2017 , ... ... for Enterprise in the category of International Trade, the UK’s most prestigious award ... international trade, which represents 95% of total revenues and has grown by a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Westside ... experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become one ... to help my numerous clients over the years with all their dental needs,” said ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology: